Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Abhijeet Kumar, MD, Jose Guillen-Rodriguez, Jonathan H. Schatz, MD, Lora Inclan, Alfonso E Ayala, Xavier Rivera, Srinath Sundararajan, MD, Faiz Anwer, MD, Daruka Mahadevan, MD PhD, Daniel O. Persky, MD, Soham D. Puvvada, MD

Blood (2016) 128 (22): 1790.

https://doi.org/10.1182/blood.V128.22.1790.1790

Published: 2016

Journal Articles

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Blood (2015) 126 (23): LBA-6.

https://doi.org/10.1182/blood.V126.23.LBA-6.LBA-6

Published: 2015

Journal Articles

Activated B-Cell DLBCL with Downstream Activation of Survival Signaling Requires PIM Kinase Activity to Maintain Oncoprotein Translation

Tara L. Peters, BA, Ana A Tula-Sanchez, PhD, Lingxiao Li, PhD, Praechompoo Pongtornpipat, BS, Mengdie WANG, BS, Nicolette BROWN, BS, Soham D. Puvvada, MD, Jonathan H. Schatz, MD

Blood (2014) 124 (21): 4496.

https://doi.org/10.1182/blood.V124.21.4496.4496

Published: 2014

Journal Articles

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Daniel O Persky, MD, Thomas P. Miller, MD, Joseph M Unger, PhD, Catherine M. Spier, MD, Soham D. Puvvada, MD, B. Dino Stea, MDPhD, Oliver W. Press, MD PhD, Louis Constine, MD, Kevin Barton, MD, Michael LeBlanc, PhD, Sonali Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 4414.

https://doi.org/10.1182/blood.V124.21.4414.4414

Published: 2014

Journal Articles

MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704

Soham D. Puvvada, MD, Patrick J Stiff, MD, Michael Leblanc, PhD, James R. Cook, MD PhD, Brad Kahl, MD, Hongli Li, M.S., Lisa M. Rimsza, MD, Jonathan W. Friedberg, MD, Sonali M. Smith, MD

Blood (2014) 124 (21): 1710.

https://doi.org/10.1182/blood.V124.21.1710.1710

Published: 2014

Journal Articles

Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1

Lingxiao Li, PhD, Praechompoo Pongtornpipat, BS, Timothy Tiutan, BS, BA, Samantha L. Kendrick, PhD, Soyoung Park, MD, Daniel O Persky, MD, Lisa M. Rimsza, MD, Soham D. Puvvada, MD, Jonathan H. Schatz, MD

Blood (2014) 124 (21): 506.

https://doi.org/10.1182/blood.V124.21.506.506

Published: 2014

Journal Articles

Targeting MYC Expression With CDK Inhibitors Shows Potency In Preclinical Models Of High-Risk Diffuse Large B-Cell Lymphom

Lingxiao Li, PhD, Praechompoo Pongtornpipat, Soham D. Puvvada, MD, Jonathan H. Schatz, MD

Blood (2013) 122 (21): 1831.

https://doi.org/10.1182/blood.V122.21.1831.1831

Published: 2013

Journal Articles

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Kevin R. Kelly, MD, PhD, Daniel O. Persky, MD, Daruka Mahadevan, MD, PhD, Thomas P. Miller, MD, Soham D. Puvvada, MD, Kevin McDonagh, MD, John Hayslip, MD, Steven I. Park, MD, Jia Ruan, MD, PhD, Peter J. Rosen, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS, Alexandra Stefanovic, MD, Bin Zhang, ScD, Xiaofei Zhou, PhD, Claudio Dansky Ullmann, MD, E. Jane Leonard, MSc, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 3027.

https://doi.org/10.1182/blood.V122.21.3027.3027

Published: 2013

Journal Articles

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Soham D. Puvvada, MD, Daniel O. Persky, MD, Lora Inclan, Jonathan H. Schatz, MD, Ellen M Chase, Jose Guillen, D Roe, Thomas P. Miller, MD

Blood (2013) 122 (21): 4404.

https://doi.org/10.1182/blood.V122.21.4404.4404

Published: 2013

Journal Articles

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

Paul M. Barr, MD, Margaret M. Briehl, PhD, Steven H Bernstein, MD, Jonathan W. Friedberg, MD, Andrea Baran, MS, Derick R. Peterson, PhD, Daniel Oscar Persky, MD, Carla Casulo, MD, Megan M. Herr, BS, Jamie Littleton, BSN, Erin Cebula, MPH, CCRP, Mark Schwartz, PhD, Soham D. Puvvada, MD, Robert T Dorr, PhD, Richard I Fisher, MD, Thomas P. Miller, MD

Blood (2013) 122 (21): 89.

https://doi.org/10.1182/blood.V122.21.89.89

Published: 2013

Journal Articles

Pharmacogenetic Approaches Identify ANTXR1 As a Potential Mediator of Response to Therapeutic NF-κB Inhibition in Diffuse Large B Cell Lymphoma

Soham D. Puvvada, MD, Cassandra L Love, Vladimir Grubor, PhD, Jenny Zhang, Jason Smith, Sandeep S. Dave, MD

Blood (2011) 118 (21): 234.

https://doi.org/10.1182/blood.V118.21.234.234

Published: 2011

Journal Articles

Selective IKKβ Inhibition of the NF-Kappab Pathway Is An Effective Therapeutic Strategy In Lymphomas

Soham D. Puvvada, MD, Jason Smith, Cassandra L Jacobs, MS, Sandeep Dave, MD

Blood (2010) 116 (21): 1849.

https://doi.org/10.1182/blood.V116.21.1849.1849

Published: 2010

NARROW

A Phase II, Open-Label Study of Bortezomib (Velcade ® ), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas

Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study

Activated B-Cell DLBCL with Downstream Activation of Survival Signaling Requires PIM Kinase Activity to Maintain Oncoprotein Translation

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

MYC Associated and Double Protein Lymphoma: Subset Analysis of SWOG S9704

Potent Efficacy of BCL2 Inhibition with ABT-199 in High-Risk Aggressive B-Lymphoma Models When Combined with Knockdown of MCL1

Targeting MYC Expression With CDK Inhibitors Shows Potency In Preclinical Models Of High-Risk Diffuse Large B-Cell Lymphom

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

Pharmacogenetic Approaches Identify ANTXR1 As a Potential Mediator of Response to Therapeutic NF-κB Inhibition in Diffuse Large B Cell Lymphoma

Selective IKKβ Inhibition of the NF-Kappab Pathway Is An Effective Therapeutic Strategy In Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only